-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $3

Benzinga·11/05/2026 21:29:08
Listen to the news
BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $4 to $3.